Preclinical research suggests that NRH may be among the most potent and efficient of NAD+ precursors, and shows promise as a new therapeutic approach to ameliorating age-related NAD+ decline “There is ...

One of the most robust forms of intellectual property protection, a composition of matter patent grants ChromaDex (CDXC) exclusive rights to the disodium salt form of NMNH ChromaDex continuously ...

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the broadening of its NAD+ precursor ...